News

PRESS RELEASE – SpinChip Diagnostics ASA secures NOK 145 million in private placement

March 22, 2024

Oslo, Norway, [22] March 2024 — SpinChip Diagnostics ASA (“SpinChip”), a pioneering diagnostics company developing a next-generation point-of-care platform for in vitro diagnostics, today announcedV the completion of its financing round, successfully securing NOK 145 million in the form of a private placement. The financing round was led by bioMérieux, a world leader in the…

Read More

Finansavisen 15. mars 2024

March 19, 2024

Henter inn fransk magnuminvestor: BioMérieux prises til 12 milliarder europå Paris-børsen og har sine røtter i Louis Pasteurs laboratorium. Nå blir selskapet neste største eier i norsk SpinChip. Les artikkelen i PDF her.

Read More

PRESS RELEASE – SpinChip Diagnostics ASA receives NOK 115 million investment from bioMérieux SA

March 14, 2024

Oslo, Norway – 14 March 2024:  SpinChip Diagnostics (“SpinChip” or the “Company”), a pioneering diagnostics company developing a next-generation point-of-care platform for in vitro diagnostics, announces that bioMérieux, a world leader in the field of in vitro diagnostics, has invested NOK 115 million in SpinChip. As a result of this transaction and depending on the…

Read More

PRESS RELEASE – SpinChip Secures NOK 43 million in Financing Round

January 8, 2024

Oslo, Norway, 8 January 2024 — SpinChip Diagnostics ASA (“SpinChip”), a pioneering diagnostics company developing a next-generation point-of-care platform for in vitro diagnostics, today announced the completion of its financing round, successfully securing NOK 43 million in the form of a convertible loan. ABG Sundal Collier and Carnegie Investment Bank acted as Joint Bookrunners for the financing round, which was…

Read More

SpinChip Diagnostics AS becomes SpinChip Diagnostics ASA

December 20, 2023

On December 4th, 2023 SpinChip Diagnostics was converted into a public limited liability company. The name of the company is now SpinChip Diagnostics ASA.

Read More

ISO 13485:2016 certification

September 14, 2023

We are excited to share that SpinChip Diagnostics has successfully obtained ISO 13485:2016 certification for our Quality Management System. In the Medical Device Industry, safety and quality are non-negotiables. At SpinChip, we strive to meet the highest standards across our QMS. This certification demonstrates our commitment to developing a safe, high-quality point-of-care platform that delivers highly…

Read More

PRESS RELEASE – SpinChip Diagnostics’ Point-of-Care platform demonstrates diagnostic performance on par with state-of-the-art clinically validated laboratory analyzers

June 8, 2023

Oslo, (8 June 2023) — SpinChip Diagnostics AS (SpinChip), a pioneering diagnostics company developing a next-generation point-of-care (POC) platform for in vitro diagnostics, today announced positive results from a diagnostic study using biobank samples from the prospective international APACE (Advantageous Predictors of Acute Coronary Syndrome Evaluation) study.   The study aimed to evaluate the diagnostic accuracy…

Read More

PRESS RELEASE – SpinChip Secures NOK 65.4 million in Financing Round

April 26, 2023

The financing round finances the design verification and sample comparison study as well as a retrospective study with 3,600 frozen patient samples. The proceeds will also finance further development of new assays as well as the start of clinical trials, ISO 13485 certification and other operating expenses. Oslo, Norway, 25 April 2023 — SpinChip Diagnostics…

Read More

Welcome Glenn Gundersen

November 16, 2022

We are excited to welcome Glenn Gundersen to the SpinChip team as our new Head of Clinical and Medical Affairs. He will be responsible for leading our clinical programs for the validation of our Point of Care biomarker assays. Glenn brings more than 25 years of experience from the MedTech and pharmaceutical industry, ranging from small and…

Read More